^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer

Published date:
03/28/2022
Excerpt:
In the phase III EMERALD trial, treatment with elacestrant significantly improved progression-free survival compared with investigator’s choice in patients with estrogen receptor-positive metastatic breast cancer that progressed on prior endocrine therapies.
DOI:
10.1093/oncolo/oyac015
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer

Excerpt:
......
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Excerpt:
...- Female or male patients with histologically confirmed ER positive (regardless of PR), HER2 negative breast cancer, according to local pathologist:...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a randomized Phase 2 evaluation of elacestrant alone or in combination with abemaciclib in women and men with brain metastases from ER positive, HER-2 negative breast cancer. Este estudio tiene 2 fases: una evaluación de Fase 1b de elacestrant en combinación con abemaciclib seguida de una evaluación randomizada de Fase 2 de elacestrant solo o en combinación con abemaciclib en mujeres y hombres con metástasis cerebrales causadas por un cáncer de mama con receptores de estrógeno y HER-2 negativo.

Excerpt:
...Patient must have ER positive, HER-2 negative tumor status as confirmed by local laboratory testing either from a fresh biopsy or from an archival tissue obtained no more than 2 years prior to signing of the informed consent form. ...